LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
YEP KC teen serves hope through enterprising volleyball benefit for men’s shelter
When 17-year-old Catherine Franano learned the mattresses at Kansas City Rescue Mission were old and too worn for comfortable use, the Pembroke High School senior leapt into action, she said. “Some of these people … like they’ve just had so many awful things happen to them, but not having anywhere to sleep?” Catherine said. “How…
(Video) ESHIP Summit attendees ask: Can entrepreneurial support efforts actually be sustainable?
When more than 600 attendees gathered this week in Kansas City for the second ESHIP Summit, they each came with their own ecosystems, businesses, local governments and support networks in mind. They also brought questions. “What are they doing in their cities? What’s worked and what hasn’t worked? What can we adopt back at home…
Four key moments led to SoftVu’s exit (three missteps kept it from happening sooner)
Deals like the acquisition of KC-based SoftVu by an Alabama private equity firm don’t happen overnight. And founder Tim Donnelly gives near-equal weight to the trials and triumphs that led the marketing platform to its big exit. “We’ve done as much as we possibly can based on the mistakes we’ve made, the lessons that have…
Eyeing added impact, AltCap expands its KC service area
AltCap — a Kansas City-based community development financial institution that focuses on underserved populations — is expanding its footprint. In response to small businesses’ growing demand for capital, AltCap will now serve the entire Kansas City metro, including the Kansas counties of Wyandotte, Johnson, and Leavenworth. The move will allow AltCap to finance more small…